Medicis Pharmaceutical Corp. (MRX) Misses Q3 EPS by 5c; Guides Q4 EPS Below Views
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q3 EPS of $0.56, $0.05 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $184.7 million versus the consensus estimate of $187.06 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.